Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button
arrow_left sharing button
arrow_right sharing button


Integrated Discovery Platform
From Concept to IND

Bispecific & Multispecific Antibody Generation


As a leading company in biologics discovery and development, experts at WuXi Biologics possess extensive experience in bispecific (bsAb) and multispecific (msAb) antibody development. We offer five, integrated discovery platforms for screening and lead identification of bispecific and multispecific antibody approaches.  The platforms include WuXiBody® , SDArBody® , SKYBody, OmniFlic®  and a standard bispecific engineering platform. Based on your R&D goals, we can offer many different bsAb and msAb platforms and formats that best suit your biology and drug development requirements.


WuXi Biologics' Suite of Bispecific Platforms



Launching A New Era in Bispecific Antibody Drug Development


WuXiBody™  is an innovative, proprietary technology platform developed by WuXi Biologics for the expanding field of bispecific antibodies. Based on novel engineering, the platform can expedite the drug development process by 6-18 months and significantly reduce production costs.  The WuXiBody platform enables almost any monoclonal antibody (mAb) sequence pair to be assembled into the bispecific construct and its unique structural flexibility makes the platform convenient to build various formats with different valency (e.g., 2, 3 or 4 binding sites).


WuXiBody Development/CMC Advantages


  • Saves 6-18 months of development time
  • Reduces manufacturing costs by as much as 90%
  • Can be used in both fed-batch and concentrated fed-batch production
  • Provides high protein expression in CHO cells (5 g/L in fed-batch, 35 g/L in concentrated fed-batch)
  • No aggregation issues
  • Very stable: >2 weeks in serum at 37 °C
  • No solubility issues: > 30 mg/ml

WuXiBody Bispecific Engineering Advantages


  • Compatible with almost any mAb sequence
  • Available in both symmetric and asymmetric formats
  • Accommodates different valency formats (bi, tri and tetra) based on project needs and biology
  • Provides same purification schemes as for mAbs
  • Ensures long in vivo half-life
  • Expected low immunogenicity (utilizes natural human sequence without complicated engineering)



SDArBody™ is a novel technology platform developed by WuXi Biologics to enable the development of multispecific proteins. This highly flexible platform offers our clients the ability to generate multispecific antibody and protein therapeutics with high affinity, low immunogenicity risk and excellent developability characteristics.


Multiple VHH lead generation and screening approaches have been developed for the SDArBody platform including traditional phage display and single B cell selection. After humanization (and optional affinity maturation), the VHH leads can be freely assembled into an SDArBody msAb. VHH-based SDArBody msAb engineering, because of its heavy chain-only advantage, was developed for our clients who prefer to start from animal immunization.






SKYBody™ is a technology platform developed by WuXi Biologics for our clients utilizing scFv (single-chain fragment variables)-based bispecific or multispecific antibodies from nearly any sequence pair. Based on extensive engineering, the platform can significantly improve scFv stability. Therefore, the bsAbs and msAbs generated using this platform contain good developability characteristics, which greatly reduces future CMC development risks.






A Common Light Chain Transgenic Rat


OmniFlic® is the first transgenic / engineered rat with a fixed light chain. The antibodies generated from this platform are then ideal for the engineering and development of fully human bispecific antibodies.


  • The “common light chain format” is an elegant technology that simplifies the purification of these IgG-type of bispecific antibodies
  • The technology allows for the maintenance of the natural molecular shape of an antibody


WuXi Biologics team of expert scientists are adept at utilizing existing bsAb formats or platforms available in the public domain (or via technologies provided by our clients) to assemble and optimize bispecific and multispecific antibodies. We have experience with over 100 different formats used in the industry (such as scFab- and scFv-based formats in the public domain).


To learn more, please read the full article “Biology drives the discovery of bispecific antibodies as innovative therapeutics” published on Antibody Therapeutics.